Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by LithLoveron Apr 04, 2021 2:34am
342 Views
Post# 32934695

Aristotle in addition to cancer testing. .

Aristotle in addition to cancer testing. .

Tripp hinted at this last year. He recently said they have been in discussions for a year. This isn't just cancer but other diseases as well that Aristotle can detect  Health Clinics/Care Oncology could be using Aristotle for more than just cancer screening  


This is from Tripps transcript for last years conference call:
 

"Gastroenterology, inflammatory bowel disease, Crohn's, these are areas that we know well. And we have both done research in these areas and published on them. The same in the cardiovascular side, the same in the muscular skeletal.

And so absolutely, as we move down the path, we will go there. We're having discussion on the scientific level with a very interesting group that is looking for inflammatory markers across the various cancers and looking for how we might be able to work with them to actually make their treatments more effective. It's very intriguing about that as you think about where you can go as it drives through."

--------------
And look at this patent by the executives of Health Clinics Ltd 
 

Publication number: 20200297850
Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
Type: Application
Filed: May 25, 2020
Publication date: September 24, 2020


https://patents.justia.com/inventor/robin-m-bannister

Heath Clinics Ltd/Care Oncology also treat chronic inflammation and pain as well as cancer.  With each disease will come more Aristotle testing and more incremental revenue. 

Also to note are the different treatments and protocols for the different cancers.  Knowing which of the 10 cancers it is makes a huge difference in treatments and protocols.  They have separate links on their website to the different cancers.  So they need to know which type of cancer or which disease they  are dealing with  again suggesting more and repeated testing   

This is a relationship that benefits both Stage and Care Oncology 

 

<< Previous
Bullboard Posts
Next >>